Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
BENICAR HCT vs TELMISARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, one tablet once daily. Initial: Telmisartan 40 mg/HCTZ 12.5 mg; titrate to max 80 mg/25 mg once daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Telmisartan: 24 hours (terminal); supports once-daily dosing with ~3-5 days to steady state. Hydrochlorothiazide: 6-15 hours (mean 10h); prolonged in renal impairment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Telmisartan: >99% biliary-fecal as unchanged drug, <2% renal. Hydrochlorothiazide: ≥95% renal as unchanged drug; minimal biliary.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB